Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.
Swiss pharmaceutical company Novartis has filed a patent infringement lawsuit against three Indian rivals in a US federal court over proposed generics of its heart failure drug Entresto.
The National Committee on IP Rights of the Philippines prevented more than PHP455 million worth of counterfeit medicines and personal care products from reaching consumers in the first seven months of this year.
The US House Committee on Energy & Commerce has voted to advance a drug pricing plan which would lower the cost of many prescription drugs.
Actavis Laboratories cannot market a generic version of Horizon Pharma’s knee pain treatment, an appeals court has ruled.
Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.
California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.
The English High Court has sided with pharmaceutical company Vectura and Novartis-owned Sandoz in a passing off lawsuit brought by rival GSK.
The US Court of Appeals for the Federal Circuit last week reversed a Patent Trial and Appeal Board decision, which found that claims in an OSI Pharmaceuticals patent for cancer treatment were obvious.
Canadian pharmaceutical company Bausch Health is suing Sandoz for patent infringement over its notice of intent to release a generic version of Xifaxan, Bausch’s irritable bowel syndrome drug.